NO782332L - Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere - Google Patents

Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere

Info

Publication number: NO782332L
Authority: NO; Norway
Prior art keywords: polymeric; ethylene oxide; molecular weight; oxyalkylenes; propylene oxide
Prior art date: 1977-07-21

Application number

NO782332A

Other languages

English (en)

Norwegian (no)

Inventor

Gerd Steinert

Harald Horstmann

Ruediger Sitt

Hans Peter Krause

Walter Puls

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-21

Filing date

1978-07-04

Publication date

1979-01-23

1978-07-04 Application filed by Bayer Ag filed Critical Bayer Ag

1979-01-23 Publication of NO782332L publication Critical patent/NO782332L/no

Links

238000000034 method Methods 0.000 title claims description 6
238000004519 manufacturing process Methods 0.000 title claims description 5
238000010521 absorption reaction Methods 0.000 title description 2
239000003112 inhibitor Substances 0.000 title description 2
150000002632 lipids Chemical class 0.000 title description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 16
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 5
125000005702 oxyalkylene group Chemical group 0.000 claims description 5
229910001854 alkali hydroxide Inorganic materials 0.000 claims description 4
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
208000020450 carbohydrate metabolism disease Diseases 0.000 claims description 2
230000000055 hyoplipidemic effect Effects 0.000 claims description 2
208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
125000006353 oxyethylene group Chemical group 0.000 claims 2
229920000642 polymer Polymers 0.000 claims 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
239000005977 Ethylene Substances 0.000 claims 1
238000006386 neutralization reaction Methods 0.000 claims 1
229920001281 polyalkylene Polymers 0.000 claims 1
239000013543 active substance Substances 0.000 description 15
229920000570 polyether Polymers 0.000 description 12
150000001875 compounds Chemical class 0.000 description 9
239000000825 pharmaceutical preparation Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 8
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
239000000969 carrier Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000004721 Polyphenylene oxide Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000008298 dragée Substances 0.000 description 4
-1 glycerol formal Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
VPWATVRHKZBOBJ-UHFFFAOYSA-K aluminum methane trihydroxide Chemical compound C.[OH-].[Al+3].[OH-].[OH-] VPWATVRHKZBOBJ-UHFFFAOYSA-K 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
239000002360 explosive Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
229940074076 glycerol formal Drugs 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229940072033 potash Drugs 0.000 description 1
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
239000001120 potassium sulphate Substances 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
238000010992 reflux Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
- C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
- C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Polymers & Plastics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polyethers (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

NO782332A 1977-07-21 1978-07-04 Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere NO782332L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19772732929 DE2732929A1 (de)	1977-07-21	1977-07-21	Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer

Publications (1)

Publication Number	Publication Date
NO782332L true NO782332L (no)	1979-01-23

Family

ID=6014492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO782332A NO782332L (no)	1977-07-21	1978-07-04	Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere

Country Status (13)

Country	Link
EP (1)	EP0000704A1 (da)
JP (1)	JPS5422497A (da)
AU (1)	AU3806878A (da)
CA (1)	CA1111453A (da)
DE (1)	DE2732929A1 (da)
DK (1)	DK324678A (da)
ES (1)	ES471900A1 (da)
FI (1)	FI782284A7 (da)
IL (1)	IL55160A0 (da)
IT (1)	IT1097831B (da)
NO (1)	NO782332L (da)
PT (1)	PT68307A (da)
ZA (1)	ZA784129B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2850058A1 (de) *	1978-11-18	1980-05-29	Bayer Ag	Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2916668A1 (de) *	1979-04-25	1980-11-13	Basf Ag	Formmassen, enthaltend styrolacrylnitril-copolymerisate und aethylenoxid-/pro- pylenoxid-dreiblockcopolymerisate, verwendung derselben und formteile aus solchen mischungen
JPS6030650B2 (ja)	1979-10-26	1985-07-17	日本油脂株式会社	座薬基剤組成物
DE3234084A1 (de) *	1982-09-14	1984-03-15	B. Braun Melsungen Ag, 3508 Melsungen	Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
DE3420708C1 (de) *	1984-06-02	1985-07-18	Hoechst Ag, 6230 Frankfurt	Modifizierte Polyethylenglykole
US5674911A (en) *	1987-02-20	1997-10-07	Cytrx Corporation	Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
AU1396588A (en) *	1987-02-20	1988-09-14	Emory University	Antiinfective compounds and method of use
US5811088A (en) *	1987-02-20	1998-09-22	Emory University	Antiinfective compounds and methods of use
US6933286B2 (en)	1991-03-19	2005-08-23	R. Martin Emanuele	Therapeutic delivery compositions and methods of use thereof
US7202225B1 (en)	1993-10-15	2007-04-10	Emanuele R Martin	Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en)	1991-03-19	2004-07-20	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
IE920860A1 (en) *	1991-03-19	1992-09-23	Cytrx Corp	Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
EP0907666A1 (en)	1996-06-27	1999-04-14	G.D. Searle & Co.	Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB610505A (en) *	1944-02-08	1948-10-18	Carbide & Carbon Chem Corp	A method for making polyoxyalkylene glycols
FR1116M (fr) *	1961-02-02	1962-02-12	Bernard Andre Francois Mirande	Utilisation de substances tensio-actives provenant de la condensation de l'oxyde d'éthylene sur les propylenes-glycols dans la résorption des oedemes locaux ou tissulaires systématisés.
ES334486A1 (es) *	1965-12-23	1967-11-01	Smith Kline & French Laboratories	Un procedimiento para la preparacion de una composicion farmaceutica que comprende la mezcla de un polimero de polioxipropileno-polioxietileno.

1977
- 1977-07-21 DE DE19772732929 patent/DE2732929A1/de active Pending
1978
- 1978-07-04 NO NO782332A patent/NO782332L/no unknown
- 1978-07-11 EP EP78100357A patent/EP0000704A1/de not_active Withdrawn
- 1978-07-17 AU AU38068/78A patent/AU3806878A/en active Pending
- 1978-07-17 PT PT68307A patent/PT68307A/pt unknown
- 1978-07-18 IL IL55160A patent/IL55160A0/xx unknown
- 1978-07-19 JP JP8721378A patent/JPS5422497A/ja active Pending
- 1978-07-19 FI FI782284A patent/FI782284A7/fi not_active Application Discontinuation
- 1978-07-19 IT IT25897/78A patent/IT1097831B/it active
- 1978-07-20 DK DK324678A patent/DK324678A/da unknown
- 1978-07-20 ES ES471900A patent/ES471900A1/es not_active Expired
- 1978-07-20 CA CA307,799A patent/CA1111453A/en not_active Expired
- 1978-07-20 ZA ZA00784129A patent/ZA784129B/xx unknown

Also Published As

Publication number	Publication date
IL55160A0 (en)	1978-09-29
IT7825897A0 (it)	1978-07-19
EP0000704A1 (de)	1979-02-21
FI782284A7 (fi)	1979-01-22
CA1111453A (en)	1981-10-27
ZA784129B (en)	1979-07-25
JPS5422497A (en)	1979-02-20
DE2732929A1 (de)	1979-02-01
DK324678A (da)	1979-01-22
PT68307A (de)	1978-08-01
ES471900A1 (es)	1979-02-01
IT1097831B (it)	1985-08-31
AU3806878A (en)	1980-01-17

Publication	Publication Date	Title
DE69818058T2 (de)	2004-07-08	Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
US4842859A (en)	1989-06-27	Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
NO782332L (no)	1979-01-23	Polyetere, fremgangsmaate til deres fremstilling samt deres anvendelse som lipidabsorbsjonshemmere
DE3040246A1 (de)	1981-05-14	Saponine, verfahren zu deren gewinnung und diese verbindungen enthaltende arzneimittel
JPS60224697A (ja)	1985-11-09	チゴゲニンセロビオシドおよび医薬
US5108750A (en)	1992-04-28	Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
DK169437B1 (da)	1994-10-31	Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen
US6376682B1 (en)	2002-04-23	Compound with α-glucosidase inhibiting action and method for producing the same
US3849561A (en)	1974-11-19	Anti-peptic ulcer substance from corydalis tubers
EP1663258A2 (en)	2006-06-07	Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans
JPS604802B2 (ja)	1985-02-06	制癌剤
CN105030716B (zh)	2019-08-16	咖啡因药物组合物及其制备方法
RU2298411C2 (ru)	2007-05-10	Применение экстрактов ginkgo biloba для получения лекарственного средства, предназначенного для лечения саркопении
US4906471A (en)	1990-03-06	Pharmaceutical composition for the reducing both hyperlipidemia and platelet-aggregation (PHP)
JP3110500B2 (ja)	2000-11-20	血糖上昇抑制剤
JP4022300B2 (ja)	2007-12-12	下剤組成物
KR100267060B1 (ko)	2001-03-02	바이플라보노이드 및 유도체를 유효 성분으로 하는 진통제
DE3218822C2 (da)	1990-10-18
JPS63170323A (ja)	1988-07-14	抗アレルギ−剤
KR100337471B1 (ko)	2002-11-30	가공인삼추출물함유신장보호제조성물
KR870002160B1 (ko)	1987-12-14	변성 점토의 제조방법
JPS625126B2 (da)	1987-02-03
KR100440607B1 (ko)	2004-07-15	프레그난 배당체 화합물 및 이를 유효성분으로 함유하는퇴행성 뇌신경계 질환의 예방 및 치료제
DE3116250C2 (da)	1988-12-22
US3914433A (en)	1975-10-21	Method of relieving the discomfort of pharyngitis